Gene · 6046
BRD2: bromodomain containing 2
12 sourcesgene-search-2026-11-11-0.2.0
Cite this record
ConductScience Library. BRD2: bromodomain containing 2. Genes, record 6046. Release gene-search-2026-11-11-0.2.0, 11 Nov 2026. https://conductscience.org/library/genes/6046
On this page
Gene
Proteins1
Reviewed human proteins whose Swiss-Prot entry states the gene.
| UniProt entry | Protein | Length | Structures | Gene stated in |
|---|---|---|---|---|
| P25440 | Bromodomain-containing protein 2 | 801 | 174 | Ensembl, GeneID, HGNC |
Source UniProt
Patents110
Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.
| Publication | Published | SEQ ID NO | Protein | Source |
|---|---|---|---|---|
| EP 4805378 A1 | 2026-09-16 | 713 | P25440 | Espacenet |
| JP 2026004568 A | 2026-01-14 | 39198 | P25440 | Espacenet |
| JP 2026004568 A | 2026-01-14 | 39199 | P25440 | Espacenet |
| JP 2026004568 A | 2026-01-14 | 39200 | P25440 | Espacenet |
| JP 2026004568 A | 2026-01-14 | 39204 | P25440 | Espacenet |
| JP 2026004568 A | 2026-01-14 | 39205 | P25440 | Espacenet |
| JP 2026004568 A | 2026-01-14 | 39215 | P25440 | Espacenet |
| JP 2026004568 A | 2026-01-14 | 39243 | P25440 | Espacenet |
| WO 2025243001 A1 | 2025-11-27 | 2 | P25440 | Espacenet |
| EP 4650780 A2 | 2025-11-19 | 9530 | P25440 | Espacenet |
1 to 10 of 110
See all 110 patentsDrugs6
Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.
| Drug | ChEMBL ID | Mechanism | Action | Source |
|---|---|---|---|---|
| APABETALONE | CHEMBL2393130 | Bromodomain and extra-terminal motif (BET) inhibitor | INHIBITOR | ChEMBL |
| BIRABRESIB | CHEMBL3581647 | Bromodomain and extra-terminal motif (BET) inhibitor | INHIBITOR | ChEMBL |
| EZOBRESIB | CHEMBL4297458 | Bromodomain and extra-terminal motif (BET) inhibitor | INHIBITOR | ChEMBL |
| MOLIBRESIB | CHEMBL1232461 | Bromodomain and extra-terminal motif (BET) inhibitor | INHIBITOR | ChEMBL |
| PELABRESIB | CHEMBL4303404 | Bromodomain and extra-terminal motif (BET) inhibitor | INHIBITOR | ChEMBL |
| RO-6870810 | CHEMBL4297423 | Bromodomain and extra-terminal motif (BET) inhibitor | INHIBITOR | ChEMBL |
Trials42
Trials of those drugs. A trial joins the gene only through a drug that acts on it.
| Trial | Drug | Phase | Results first posted | Source |
|---|---|---|---|---|
| NCT07357727 | PELABRESIB | PHASE3 | ClinicalTrials.gov | |
| NCT07340138 | PELABRESIB | PHASE1 | ClinicalTrials.gov | |
| NCT06590324 | APABETALONE | PHASE2/PHASE3 | ClinicalTrials.gov | |
| NCT06401356 | PELABRESIB | PHASE3 | ClinicalTrials.gov | |
| NCT05372354 | EZOBRESIB | PHASE1/PHASE2 | ClinicalTrials.gov | |
| NCT04915300 | APABETALONE | PHASE2 | ClinicalTrials.gov | |
| NCT04894266 | APABETALONE | PHASE2/PHASE3 | ClinicalTrials.gov | |
| NCT04817007 | EZOBRESIB | PHASE1/PHASE2 | ClinicalTrials.gov | |
| NCT04603495 | PELABRESIB | PHASE3 | 2024-10-28 | ClinicalTrials.gov |
| NCT03936465 | EZOBRESIB | PHASE1 | ClinicalTrials.gov |
1 to 10 of 42
See all 42 trialsNIH grants2,589
NIH grants whose papers are about the gene, through NIH's grant-paper links.
| Grant | Title | BRD2 papers | Newest fiscal year |
|---|---|---|---|
| P30CA016672 | Cancer Center Support Grant | 19 | 2025 |
| P30CA008748 | Cancer Center Support Grant | 16 | 2025 |
| R35CA197589 | Inducing Proximity: An Emerging Paradigm for New Therapeutic Modalities | 13 | 2025 |
| P30CA010815 | Consolidated Basic Cancer Research Program | 12 | 2025 |
| P30CA021765 | Cancer Center Support Grant (CCSG) | 12 | 2025 |
| P30AI027763 | UCSF-Bay Area Center for AIDS Research | 10 | 2025 |
| P30CA046592 | University of Michigan Rogel Cancer Center Support Grant 2023-2028 | 10 | 2025 |
| P30CA068485 | Cancer Center Support Grant | 10 | 2025 |
| P30CA076292 | Moffitt Cancer Center Support Grant | 10 | 2025 |
| P01CA066996 | Development of Novel Therapeutic Strategies in Human Leukemias | 8 | 2025 |
1 to 10 of 2,589Source NIH's project files
See all 2,589 nih grantsPapers3,414
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| MAPK signaling links BRD2 chromatin occupancy to PI3K/AKT inhibitor sensitivity. | bioRxiv | 2026 | 42818240 | PubTator, text mining | PubMed |
| Correction to 'INO80/SWR remodelers regulate Pol II transcription through BRD2 and chromatin landscape'. | Nucleic Acids Res | 2026 | 42741843 | PubTator, text mining | PubMed |
| BRD2-Mediated TGR5 destabilization impairs fatty acid oxidation and drives tubular ferroptosis in diabetic kidney injury. | Free Radic Biol Med | 2026 | 42685932 | PubTator, text mining | PubMed |
| BRD4: From molecular understanding to therapeutics development. | Mol Cell | 2026 | 42492506 | PubTator, text mining | PubMed |
| Neuroinflammation- molecular target based therapeutic approach. | Adv Protein Chem Struct Biol | 2026 | 42448410 | PubTator, text mining | PubMed |
| Targeting bromodomain and extraterminal proteins in cardiovascular disease: Pathological mechanisms and therapeutic applications. | J Int Med Res | 2026 | 42426583 | PubTator, text mining | PubMed |
| Epigenetic regulation of cardiac physiology and pathophysiology: biological sex matters. | J Cardiovasc Aging | 2026 | 42369572 | PubTator, text mining | PubMed |
| Single-cell and spatial transcriptomic colocalization analysis reveals the roles of histone deacetylation in lung adenocarcinoma progression and microenvironment. | Transl Res | 2026 | 42336135 | PubTator, text mining | PubMed |
| Identification of macrophage-enriched genes in ovarian cancer by single-cell RNA sequencing and establishment of a prognosis model. | Sci Rep | 2026 | 42324278 | PubTator, text mining | PubMed |
| EVs-MSC alleviate RA progression via USP21-dependent BRD2 stabilization to regulate autophagy in FLS. | Biochem Pharmacol | 2026 | 42302977 | PubTator, text mining | PubMed |
1 to 10 of 3,414
See all 3,414 papersSources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this gene from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/genes/v1/6046
GET https://conductscience.org/api/genes/v1/6046/patents?page=2